Despite the government's decision to limit reimbursement, the brain function-improving drug Choline Alfoscerate continues to come out with price cuts due to increased usage. It was found that 6 Choline Alfoscerate items were included in the PVA type Da negotiations this year as well. According to the industry on the 7th, negotiations were conducted as Gliatamin drugs such as Gliatamin were included in the Type Da target this year. Choline Alfoscerate ingredient items that have been negotiated are Ahn-gook Kanoa Soft Cap., Korea Prime Pharmaceuticals Gria Soft, Daewoong Bio Gliatamine Soft Cap, and Gliatamine.

They negotiated for the number of claims in 2022 to exceed the PVA Type Da standard. Criteria f